7 comments

  • mft_ 19 minutes ago

    For once, this isn’t hyperbole. Metastatic pancreatic cancer hasn’t had a meaningful new treatment in literally decades - it’s been brutal chemotherapy or slightly less brutal chemotherapy.

    The new generation of KRAS inhibitors, of which daraxonrasib is just the first to make it to approval, is genuinely a practice-changing breakthrough.

    It won’t cure people with metastatic disease, but it will help a lot live better lives for longer.

    • 233mhz 14 minutes ago

      > For once, this isn’t hyperbole.

      Am I missing something?

      From other sources:

      > Median overall survival: 13.2 months versus about 6.6 to 6.7 months with chemotherapy.

      • scarmig 11 minutes ago

        Doubling life expectancy on a form of cancer infamous as a death sentence.

        • shevy-java 2 minutes ago

          I don't see that as a breakthrough.

          Merely counting months does not do much - you'd have to count the quality of these months too.

      • tedggh 7 minutes ago

        Everything is relative. A few more months of life with less pain and more energy to spend it with family surely is a breakthrough for many patients and for the doctors treating them.

        • shevy-java a minute ago

          But where does it imply less pain? Plus, which pain exactly? Chemotherapy also leads to pain. Prolonging treatment can cause more pain then.

          I don't see that as a breakthrough.

  • dang 26 minutes ago

    In case others are wondering, it looks like this is a different story than this recent one:

    Pancreatic cancer halted by virus injection in three patients - https://news.ycombinator.com/item?id=50563066 - Nov 2026 (157 comments)